Companies · Other Health Care

Colorescience Inc

Carlsbad · Other Health Care

Diligence memoA one-page analyst read on Colorescience Inc — recommendation, valuation, rhythm, risks.
$51.2M
Total raised · real
6
Rounds
0.8×
Latest step-up
Top 9%
Sector rank · raised
Series B
Latest stage · inferred · Fri Jan 24 2020 00:00:00 GMT+0000 (Coordinated Universal Time)

Colorescience Inc looks under-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the health care sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.18× the median modeled value of Series B Other Health Care companies in 2019–2021 (78 peers) — value vs value, same stage and era.
Dormant
  • Last raise 6.4 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Other Health Care

Colorescience Inc is one of 5376 Other Health Care companies tracked from Carlsbad. By capital raised it ranks among the largest (ahead of 92% of sector peers), and in the upper tier by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
10
Investors (latest)
2020-01-24
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$125M$250M$375M$500MSeries A · 2013-05-17 Raised $10M (real) Modeled valuation $202M (est)$10M$202MSeries A2013Series A · 2014-09-09 Raised $15M (real) Modeled valuation $303M (est)$15M$303MSeries A2014Series A · 2017-03-22 Raised $4.2M (real) Modeled valuation $85M (est)$4.2M$85MSeries A2017Series B · 2017-07-06 Raised $15M (real) Modeled valuation $333M (est)$15M$333MSeries B2017Series B · 2018-05-18 Raised $4.0M (real) Modeled valuation $89M (est)$4.0M$89MSeries B2018Series B · 2020-01-24 Raised $3.0M (real) Modeled valuation $66M (est)$3.0M$66MSeries B2020+$15M+$4.2M+$15M+$4.0M+$3.0MCumulative $51M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series A$10.0M · 2013
Series A extension$15.0M · 2014
Series A extension$4.2M · 2017
Series B$15.0M · 2017
Series B extension$4.0M · 2018
Series B extension$3.0M · 2020

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 50%.

Modeled valuation trajectory
$66.5M
Base estimate est.
$7.0M
Conservative case
$255.8M
Upside case
$16.7M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ba $15M–$40M round). Valuation is modeled from stage benchmarks scaled by the health care sector profile. Directional, not a quoted figure.

Series A · modeled $201.8M · 2013-05-172013Series A · modeled $302.7M · 2014-09-09Series A · modeled $84.7M · 2017-03-22Series B · modeled $332.8M · 2017-07-06Series B · modeled $88.6M · 2018-05-18Series B · modeled $66.5M · 2020-01-242020
Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
64%
Survival probability
42% low · 78% high
1.36×/yr
Annual markup
1.64×/yr upside case
6.0 yr
Elapsed time used
6.4 yr actual, capped for stale marks
health care
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
16 mo
Avg between rounds
$7.7M/yr
Capital velocity
13.1 yr
On record since
2013
First round
6
Rounds on file
How it compares to the market

Benchmarked against 5376 companies in Other Health Care. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 21× above median
This company$51.2M
Sector median$2.4M
Latest round — vs other Series B rounds in sector (real $, this stage) 0.2× of median
This company$3.0M
Sector median$17.8M
Modeled value — vs sector median (estimate, all stages) 3.0× above median
This company$66.5M
Sector median$22.1M

Raised more than 92% of sector peers (real $). Modeled value above 71% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series B) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #69 of 78.

This companyCohort peer
$10.0M$100.0M$1.0B$10.0B$10.0M$100.0MCapital raised (log)KSMS Holdings, LLC · Series B Raised $40.0M · modeled $885.1M (est)Infab HoldCo, Inc. · Series B Raised $36.5M · modeled $807.5M (est)Aquity Holdings, Inc. · Series B Raised $36.0M · modeled $797.6M (est)MHH Management Holdco, LLC · Series B Raised $35.1M · modeled $777.6M (est)Earli Inc. · Series B Raised $40.0M · modeled $756.4M (est)Encore Dermatology, Inc. · Series B Raised $89.6M · modeled $729.9M (est)National Spine & Pain Centers Holdings, LLC · Series B Raised $32.0M · modeled $708.9M (est)In Vitro Sciences, LLC · Series B Raised $31.5M · modeled $697.9M (est)Lotus Parent, Inc. · Series B Raised $31.2M · modeled $690.4M (est)Iron Oak Holdings LLC · Series B Raised $30.0M · modeled $664.6M (est)Squid Ink, Inc. · Series B Raised $30.2M · modeled $620.8M (est)Predict Innovation Investors, Llc · Series B Raised $27.9M · modeled $617.4M (est)Colorescience Inc (this company) Raised $51.2M · modeled $66.5M (est)Colorescience Inc
CompanyStageRaised · realValue · estvs peer med.
KSMS Holdings, LLCSeries B$40.0M$885.1M2.37×
Infab HoldCo, Inc.Series B$36.5M$807.5M2.16×
Aquity Holdings, Inc.Series B$36.0M$797.6M2.13×
MHH Management Holdco, LLCSeries B$35.1M$777.6M2.08×
Earli Inc.Series B$40.0M$756.4M2.02×
Encore Dermatology, Inc.Series B$89.6M$729.9M1.95×
National Spine & Pain Centers Holdings, LLCSeries B$32.0M$708.9M1.90×
In Vitro Sciences, LLCSeries B$31.5M$697.9M1.87×
Lotus Parent, Inc.Series B$31.2M$690.4M1.85×
Iron Oak Holdings LLCSeries B$30.0M$664.6M1.78×
Squid Ink, Inc.Series B$30.2M$620.8M1.66×
Predict Innovation Investors, LlcSeries B$27.9M$617.4M1.65×
Colorescience Inc this companySeries B$51.2M$66.5M0.18×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series A$10.0M2013-05-17$45.5M$201.8M85%
Series A$15.0M2014-09-09$68.2M$302.7M85%
Series A$4.2M2017-03-22$19.1M$84.7M90%
Series B$15.0M2017-07-06$83.5M$332.8M90%
Series B$4.0M2018-05-18$22.2M$88.6M90%
Series B$3.0M2020-01-24$16.7M$66.5M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series A$10.0M2013-05-17
    • First recorded raise — entered as Series A.
    • 53 investors on this round.
  2. Series A$15.0M2014-09-09
    • Raised 16 mo later, in step with the ~14 mo sector norm.
    • Round 1.5× larger than the prior — scaling up.
    • Switched to Rule 506(b) (was Rule 06).
    • 32 investors on this round.
  3. Series A$4.2M2017-03-22
    • Raised again after 30 mo — slower than the ~14 mo sector norm.
    • Round 3.6× smaller than the prior — bridge or down round.
    • 32 investors on this round.
  4. Series B$15.0M2017-07-06
    • Came back fast: 3 mo vs the ~14 mo sector norm.
    • Round 3.6× larger than the prior — scaling up.
    • 34 investors on this round.
  5. Series B$4.0M2018-05-18
    • Raised 10 mo later, in step with the ~14 mo sector norm.
    • Round 3.8× smaller than the prior — bridge or down round.
    • 17 investors on this round.
  6. Series B$3.0M2020-01-24
    • Raised 20 mo later, in step with the ~14 mo sector norm.
    • Round 1.3× smaller than the prior — bridge or down round.
    • 10 investors on this round.
Intelligence
2021 ~Q2
Modeled next raise · ~16mo cadence
$3.0M
Modeled next size est.range $3.0M$4.8M
0.8×
Last step-up
$7.7M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
David F Hale15 other2013-05
Alex Morgan9 other2018-05
Adele Oliva8 other2017-07
Brian H. Dovey6 other2013-05
Josh Baltzell6 other2017-07
Joshua J. Baltzell4 other2013-05
James H. Cavanaugh, Ph.D.2 other2013-05
Mary Fisher2 other2017-03
Richard Aldrich2 other2018-05
James Cavanaugh, Ph.D.1 other2017-03
Jessica Hou1 other2020-01
Theodore Ebel1 other2017-07
Brian F. Dovey2017-03
Daniell F. Turner III2017-03
David H. Crist2013-05
David Olsen2018-05
George M. Jenkins2013-05
Howard D. Palefsky2013-05
James M. Cavanaugh, Ph.D.2014-09
Josh F. Baltzell2017-03
Josh J. Baltzell2014-09
Josie O. Juncal-Schwarz2014-09
Lynelle D. Lynch2014-09
Mary M. Fisher2013-05
Registry & provenance

Colorescience Inc is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1578302
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Skinmedica IncPharmaceuticalsSeries B$26.2M$569.9Mnetwork5 shared operators · same stage
Greenbrook TMS Inc.Other Health CareSeries B$50.6M$187.0Mnetwork1 shared operator · same sector · same stage
NovaSom, IncOther Health CareSeries B$53.9M$82.0Mnetwork1 shared operator · same sector · same stage
Encore Dermatology, Inc.Other Health CareSeries B$89.6M$729.9Mnetwork1 shared operator · same sector · same stage
Sleep Solutions IncOther Health CareSeries B$20.0M$443.1Mnetwork1 shared operator · same sector · same stage
Cardionomic, Inc.Other Health CareSeries B$51.7M$76.2Msame sector · same stage
AVAVA, Inc.Other Health CareSeries B$48.8M$77.9Msame sector · same stage
ColorescienceOtherSeries B$15.3M$253.5Mnetwork2 shared operators · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Color Holdings, L.P.Other Health CareSeries C$1.1B88%
Physcient, Inc.Other Health CareSeed$3.3M88%
Mindsciences, Inc.Other Health CareSeed$60.5M87%
Phenomix Sciences, Inc.Other Health CareSeries A$7.1M85%
Gene Sciences, Inc.Other Health CareSeries A$161.4M85%
Lightspeed Microscopy, Inc.Other Health CareSeries A$16.2M85%
Brighter Inc.Other Health CareSeries B$576.0M85%
Verdant Scientific, Inc.Other Health CarePre-Seed$561K85%
Frequently asked
How much funding has Colorescience Inc raised?
Colorescience Inc has raised approximately $51.2M in disclosed capital across 6 recorded financing rounds, aggregated from public filings.
What is Colorescience Inc's estimated valuation?
Provath's modeled valuation for Colorescience Inc is approximately $66.5M (modeled range $7.0M–$255.8M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Colorescience Inc at?
Colorescience Inc's latest modeled financing stage is Series B. Its most recent recorded round closed around Fri Jan 24.
What does Colorescience Inc do and where is it based?
Colorescience Inc operates in the Other Health Care sector, based in Carlsbad.
Explore related

See where Colorescience Inc sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Colorescience Inc, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.